1. Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study
- Author
-
Rubén Martín-Escolano, Ana Virseda-Berdices, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, Amanda Fernández-Rodríguez, Cristina Díez, Victor Hontañon, The Marathon Study Group, Salvador Resino, María Ángeles Jiménez-Sousa, A. Arranz, F. Arnalich, J. R. Arribas, E. Aznar, T. Aldamiz-Echevarría, J. Bermejo, J. Berenguer, J. M. Bellón, I. Bernardino, M. J. Bustinduy, A. Carrero, S. Carretero, E. Casas, J. L. Casado, M. Crespo, P. Crespo, C. Díez, M. Díaz, J. de Miguel, F. Dronda, H. Esteban, C. Fanciulli, A. Ferrer, M. J. Galindo, J. González-García, I. Gutiérrez, A. Iribarren, V. Hontañón, C. López, P. Miralles, M. L. Montes, A. Moreno, S. Moreno, L. Ortiz, E. Ortega, B Padilla, J. F. Parras, L. Pérez-Latorre, F. Pascual, M. Pérez, M. J. Pérez-Elías, J. M. Peña, C. Quereda, M. Ramírez, E. Ribera, J. F. Rodríguez-Arrondo, J. Sanz, I. Santos, M. A. Sanfrutos, S. Schroeder, F. Tejerina, M. J. Téllez, E. Van den Eynde, J. Vergas, M. A. Von-Wichmann, M. Yllescas, and J. F. Zamora
- Subjects
HIV/HCV-coinfection ,HCV therapy ,immune checkpoint proteins ,type 2 diabetes mellitus ,dyslipidemia ,TyG index ,Therapeutics. Pharmacology ,RM1-950 - Abstract
BackgroundUnderstanding the predictors of metabolic disorders in persons with HIV/HCV coinfection post-HCV therapy is crucial for improving patient outcomes. Since immune checkpoint proteins are usually upregulated in these persons with HIV/HCV coinfection, we aimed to evaluate the association between plasma immune checkpoint proteins at baseline (before HCV therapy) and metabolic disturbances during the follow-up (about 5 years after successful HCV treatment) in persons with HIV/HCV coinfection.MethodsWe performed a retrospective study on 80 persons with HIV/HCV coinfection with advanced fibrosis or cirrhosis who cleared HCV infection after successful HCV therapy and were followed for about 5 years after completion of HCV treatment. Plasma samples were collected at baseline. Immune checkpoint proteins were analyzed using a Luminex 200™ analyzer. Outcomes were the development of a metabolic event (type 2 diabetes mellitus and/or dyslipidemia) and the change in Triglycerides and glucose (TyG) index.ResultsDuring follow-up, 21 (26%) patients developed metabolic events (type 2 diabetes mellitus/dyslipidemia), and 29 (46.0%) patients had an increase in TyG during the follow-up. Low baseline values of BTLA and LAG-3, two immune checkpoint proteins, were associated with the development of metabolic events (aAMR = 0.69 and aAMR = 0.71, respectively) and with increases in TyG values (aAMR = 0.72 and aAMR = 0.70, respectively). In addition, other immune checkpoint proteins were also inversely associated with increases in TyG.ConclusionWe discovered that low plasma levels of BTLA and LAG-3 before HCV therapy significantly correlate with an increased risk of developing metabolic disorders after treatment.
- Published
- 2024
- Full Text
- View/download PDF